ReviewGlobal heart2022
Mesenchymal Stem Cell (MSCs) Therapy for Ischemic Heart Disease: A Promising Frontier.
Review in Global heart, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Therapeutic potential of dental mesenchymal stem cells versus mesenchymal stem cells from other sources: a systematic review of animal studies.BMC oral health · 2025Pooled it
- Cardiac Repair and Mesenchymal Stem Cells: Exploring New Frontiers in Regenerative Medicine.Current cardiology reviews · 2026Review
- Article
- Therapeutic Potential and Mechanisms of Mesenchymal Stem Cells in Coronary Artery Disease: Narrative Review.International journal of molecular sciences · 2025Review
- Navigating mesenchymal stem cells doses and delivery routes in heart disease trials: A comprehensive overview.Regenerative therapy · 2025Review
- The therapeutic efficacy comparison of MSCs derived different tissues unveilings anti-apoptosis more crucial than angiogenesis in treating acute myocardial infarction.Stem cell research & therapy · 2025Article
- Review
- From bench to bedside: translating mesenchymal stem cell therapies through preclinical and clinical evidence.Frontiers in bioengineering and biotechnology · 2025Review
- Cardiac preservation usingFrontiers in cardiovascular medicine · 2025Article
- From laboratory to clinic: a precise treatment strategy of mesenchymal stem cells-derived exosomes pretreated by simulating disease microenvironment.Frontiers in immunology · 2025Review
- Review
- The Potential of Mesenchymal Stem Cell-Derived Exosomes in Cardiac Repair.International journal of molecular sciences · 2024Review
- Transcriptomic analysis of BM-MSCs identified EGR1 as a transcription factor to fully exploit their therapeutic potential.Biochimica et biophysica acta. Molecular cell research · 2024Article
- Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists.Oncotarget · 2024Review
- Recent Insights into Endogenous Mammalian Cardiac Regeneration Post-Myocardial Infarction.International journal of molecular sciences · 2024Review
- Mesenchymal stem cell-derived cell-free technologies: a patent landscape.Biotechnology letters · 2024Review
- Chemical Hypoxic Preconditioning Improves Survival and Proliferation of Mesenchymal Stem Cells.Applied biochemistry and biotechnology · 2024Article
- Single high-dose intravenous injection of Wharton's jelly-derived mesenchymal stem cell exerts protective effects in a rat model of metabolic syndrome.Stem cell research & therapy · 2024Article
- Stem cell-based therapies for heart failure management: a narrative review of current evidence and future perspectives.Heart failure reviews · 2024Review
- Human umbilical cord-derived mesenchymal stromal cells improve myocardial fibrosis and restore miRNA-133a expression in diabetic cardiomyopathy.Stem cell research & therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although tremendous progress has been made in conventional treatment for ischemic heart disease, it still remains a major cause of death and disability. Cell-based therapeutics holds an exciting frontier of research for complete cardiac recuperation. The capacity of diverse stem and progenitor cells to stimulate cardiac renewal has been analysed, with promising results in both pre-clinical and clinical trials. Mesenchymal stem cells have been ascertained to have regenerative ability via a variety of mechanisms, including differentiation from the mesoderm lineage, immunomodulatory properties, and paracrine effects. Also, their availability, maintenance, and ability to replenish endogenous stem cell niches have rendered them suitable for front-line research. This review schemes to outline the use of mesenchymal stem cell therapeutics for ischemic heart disease, their characteristics, the potent mechanisms of mesenchymal stem cell-based heart regeneration, and highlight preclinical data. Additionally, we discuss the results of the clinical trials to date as well as ongoing clinical trials on ischemic heart disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.